Journal
ACS CATALYSIS
Volume -, Issue -, Pages -Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acscatal.1c05567
Keywords
threonine aldolase (TA); pyridoxal-5'-phosphate (PLP); beta-hydroxy-alpha-amino acids (HAAs); catalytic mechanism; QM/MM; ONIOM
Categories
Funding
- Applied Molecular Biosciences Unit-UCIBIO
- Associate Laboratory i4HB
- FCT [2020.01423.CEECIND, 01/SAICT/2016, 022153, CPCA/A00/7140/2020, CPCA/A00/7145/2020]
- FEDER [UIDP/04378/2020]
- [UIDB/04378/2020]
- [LA/P/0140/2020]
- [PTDC/QUI-QFI/31689/2017]
- [SFRH/BD/136746/2018]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/136746/2018] Funding Source: FCT
Ask authors/readers for more resources
The catalytic mechanism of threonine aldolase was studied in detail using computational methods, revealing a three-step process with the covalent bond cleavage as the rate-limiting step. These findings are valuable for optimizing the synthesis of beta-hydroxy-alpha-amino acids, which are important building blocks in various commercial drugs.
The catalytic mechanism of threonine aldolase (TA) was herein studied in atomic detail employing the computational ONIOM hybrid QM/MM methodology. TA is a PLP-dependent enzyme that catalyzes the retro-aldol cleavage of threonine into glycine and acetaldehyde, as well as the reverse reaction. This enzyme is currently seen as the optimal approach for the regioselective synthesis of beta-hydroxy-alpha-amino acids (HAAs), which are very difficult to obtain by standard methods. The results obtained herein show that the catalytic mechanism of TA occurs in three steps: (i) deprotonation of the hydroxyl group of EA1, (ii) covalent bond cleavage, and (iii) hydrolysis. According to the Gibbs free energy profile, the rate-limiting step of the catalytic process is the covalent bond cleavage, which results in the formation of acetaldehyde. The calculated energy barrier for this step is 16.7 kcal mol(-1), which agrees very well with the kinetic data available in the literature (17.4 kcal mol(-1)). All these results can now be used for the optimization of the synthesis of HAAs that serve as building blocks of several commercial drugs, such as antibiotics, immunosuppressants, and the anti-Parkinson's disease drug L-threo-3,4-dihydroxyphenylserine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available